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Background: Mutations of the gene encoding the major component of Lewy bodies (LB), α-synuclein (α-syn), cause
autosomal dominant forms of Parkinson’s disease (PD), whereas loss-of-function mutations of the gene encoding
the multifunctional E3 ubiquitin-protein ligase Parkin account for autosomal recessive forms of the disease. Parkin
overproduction protects against α-syn-dependent neurodegeneration in various in vitro and in vivo models, but it
remains unclear whether this process is affected by Parkin deficiency. We addressed this issue, by carrying out more
detailed analyses of transgenic mice overproducing the A30P variant of human α-syn (hA30Pα-syn) and with two, one
or no parkin knockout alleles.
Results: Longitudinal behavioral follow-up of these mice indicated that Parkin depletion delayed disease-
predictive sensorimotor impairment due to α-syn accumulation, in a dose-dependent fashion. At the end stage of the
disease, neuronal deposits containing fibrillar α-syn species phosphorylated at S129 (PS129α-syn) were the predominant
neuropathological feature in hA30Pα-syn mice, regardless of their parkin expression. Some of these deposits colo-
calized with the LB markers ubiquitin and α-syn truncated at D135 (α-synD135), indicating that PS129α-syn is subjected
to secondary posttranslational modification (PTM); these features were not significantly affected by parkin dysfunction.
Conclusions: These findings suggest that Parkin deficiency acts as a protective modifier in α-syn-dependent
neurodegeneration, without overtly affecting the composition and characteristics of α-syn deposits in end-stage disease.
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Biochemical studies of α-syn within Lewy bodies (LB) re-
vealed various posttranslational modifications (PTM) of
the protein, some of which are associated with Parkinson’s
disease (PD) and other synucleinopathies (for a recent re-
view on α-syn PTM, see [1]). The most abundant α-syn
PTM is phosphorylation: nearly 90% of the molecules of
this protein in LB are phosphorylated at S129 (PS129α-syn)
[2,3]. α-Syn is also ubiquitylated [2,4-6]; various lysine res-
idues affected by this PTM have been identified, mostly in* Correspondence: olga.corti@upmc.fr
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reproduction in any medium, provided the orthe N-terminal part of the protein [2,7,8]. Ubiquitin has
been shown to be primarily associated with PS129α-syn
[2,4,5], raising the possibility of crosstalk between the
two modifications. In addition, about 15% of α-syn is
truncated in LB [9,10] and various C-terminally cleaved
α-syn species (e.g. D135, Y133, N122, D119, D115) have
been identified [2,4,9-12]. All these α-syn species have
been shown to accumulate in animal models of α-
synucleinopathy [11,13-24], but they have mostly been
studied independently of each other. Thus, the interplay
between them remains poorly understood.
Most early-onset autosomal recessive cases of PD are
due to mutations in the gene encoding Parkin [25,26], an
E3 ubiquitin-protein ligase involved in the ubiquitylationl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lin, p38/JTV1/AIMP2, Eps15) and in various cellular
mechanisms, including signaling pathways, synaptic trans-
mission, proteasomal protein degradation and the autoph-
agy of dysfunctional mitochondria [25,27]. It is unclear
whether mutations in the α-syn and parkin genes con-
verge into common neuropathological pathways. The
overproduction of Parkin protects against α-syn-induced
toxicity, both in vitro and in vivo [19,28-30], but conflict-
ing results have been reported in models of Parkin deple-
tion, which mimics the loss of protein function underlying
PD due to parkin mutations [16,31].
We explored this issue further, in mice producing the
pathogenic human A30P variant of α-syn (hA30Pα-syn).
Transgenic hA30Pα-syn mice are a well described model
of α-synucleinopathy, characterized by an age-dependent
lethal movement disorder associated with the deposition
of proteinase K-resistant α-syn, PS129α-syn and ubiquitin
throughout the central nervous system [16,21,32]. We
previously reported that Parkin deficiency due to biallelic
gene knockout delays the onset of the neurodegenerative
phenotype in this model [16]. In this study, we used a set
of behavioral tests to monitor the development of motor
dysfunction in hA30Pα-syn mice with two, one or no
functional parkin alleles. We also provide a detailed im-
munohistochemical description of the α-syn deposits, to
clarify the relationships between the various PTM of the
protein and the effects of an absence of Parkin. We report
that dysfunctional parkin alleles delay the onset of disease
signs, in a dose-dependent manner, in hA30Pα-syn mice,
with only modest effects on neuropathological character-
istics in end-stage disease.
Methods
Ethics statement
All experiments involving mice were approved by the
Ile-de-France Regional Ethics Committee for Animal Ex-
periments, Nu3 (P3/2006/006). Post-mortem samples of
PD patients were obtained from brains collected in a Brain
Donation Program of the Brain Bank “GIE NeuroCEB”,
run by a consortium of Patient Associations: ARSEP (asso-
ciation for research on multiple sclerosis), CSC (cerebellar
ataxias), France Alzheimer and France Parkinson. Consents
were signed by the patients or their next of kin in their
name, in accordance with French bioethics law. The ap-
proval for the collection of samples in the Brain Bank has
been granted by the Ministry of Higher Education and Re-
search (authorization #AC 2007–5).
Behavioral analyses
Experimental groups of female littermate mice were gene-
rated, genotyped and housed, as previously described [16].
In brief, homozygous parkin knockout mice [33] brought
into the C57Bl/6j genetic background by an acceleratedbackcross procedure were bred with homozygous hA30Pα-
syn mice brought into a C57Bl/6j background by eight con-
secutive backcrosses [21]. Mice of the double-heterozygous
generation were then crossed to generate littermates of the
nine expected genotypes. Age-matched littermates of the
genotypes of interest were used for all subsequent analyses.
Behavioral studies were performed in the mornings of
two consecutive days, by investigators blind to genotype.
The animals were weighed, and behavioral tasks were per-
formed in the following order: 1) extension reflex, 2)
rotarod test and 3) footprint test. The symmetry of the
hindlimb extension reflex and the time spent on a rotating
rod were studied as previously described [16]. The ampli-
tude of the extension reflex was characterized as follows: 5-
swift and wide, 4- normal, 3- mild, 2- narrow, 1- little
movement 0- no extension. On this scale, 3 was considered
to correspond to an abnormally low score, because it was
not observed in control groups; a score of 2 or 1 was in-
variably accompanied by an abnormal gait. For the foot-
print test, the hindpaws and forepaws were inked with
different colors and the animal was placed at the entrance
of a corridor (10 cm long x 5 cm wide x 5 cm high) cov-
ered with a paper sheet; the mouse was allowed to walk
through without pause. Based on consecutive imprints, we
measured the length and width of four steps for the fore-
limbs and hindlimbs.
Qualitative and quantitative immunofluorescence analyses
Three cases of sporadic PD and an age-matched control
without neurological lesions were selected from the
Escourolle Neuropathology Laboratory of Pitié-Salpêtrière
Hospital. The PD cases were characterized histopatho-
logically for neuron loss from the substantia nigra and for
the presence of LB, as previously described [34]. All histo-
logical immunofluorescence staining was performed as
described by Vitte et al. [34], after bleaching to eliminate
the autofluorescence of the human tissue, by incubating
the sections in phosphate-buffered saline (PBS) for 2 h
under the light of a desk lamp at 4°C. All immunohisto-
chemical analyses in animals were performed in homozy-
gous hA30Pα-syn+/+ mice with (parkin−/−) or without
Parkin deficiency. Animals were killed in the end stage of
the disease, about three weeks after the onset of symp-
toms, and the brain was removed and processed for im-
munohistochemistry, as previously described [16]. For
preabsorption experiments, an antibody directed against
α-syn truncated at D135 (α-synD135) was first incubated
for 6 h in PBS supplemented with 4% bovine serum albu-
min (BSA), 10% newborn goat serum (NGS) with the re-
combinant proteins of interest (α-synD135, α-synY133
and α-syn), at an antibody:protein ratio of 1:2000. The
proportion of LB detected by PS129α-syn staining also dis-
playing α-synD135 labeling was estimated on 50 LB from
the three cases of PD. The percentage of cell bodies and
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fied in two or three representative 5 μm-thick coronal
brainstem sections selected on the basis of staining abun-
dance and observed with an epifluorescence microscope
(magnification x63, Axioplan 2, Zeiss, Germany). We
scored about 50 neuronal cell bodies and 100 processes,
identified on the basis of morphology and DAPI staining,
for each animal, and six to ten animals from each geno-
type were analyzed. Brightfield images were acquired with
a multipurpose zoom microscope (NIKON AZ100)
and NIS software. Colocalization of different types of
immunofluorescent labeling was further analyzed with
a confocal microscope (Leica SP2 AOBS, Wetzlar,
Germany) and a x63 objective. Z-stack images, with
0.2 μm Z-intervals covering entire immunostained vol-
umes within individual cell bodies or processes (n = 6
structures), were taken from representative animals
(n = 3) for each relevant genotype. The degree of co-
localization was determined by calculating Pearson’s
coefficient with the JACoP plug-in of ImageJ software.
Immunostaining for electron microscopy
Mice were anesthetized with pentobarbital (130 mg/kg,
i.p.; Sigma, St Quentin, France) and perfused trans-
cardially with 4% PFA freshly prepared in PBS supple-
mented with 0.01% glutaraldehyde. Brains were removed
and post-fixed by incubation overnight in 4% PFA. Sections
from the brainstem (45 μm thick), which has been show to
contain abundant PS129α-syn deposits, were obtained with
a vibratome (HM 650 V Microm International), immunola-
beled for PS129α-syn and then incubated with 3,3'-diamino-
benzidine (DAB) or gold [35]. Ultrathin sections (60 nm)
were analyzed with a JEOL 1200EX II electron microscope
at 80 kV (Akishima, Japan).
Antibodies
Mouse monoclonal anti-α-synD135 and anti-α-synY133
antibodies were generated essentially as previously de-
scribed [2], with the peptides CGGEEGYQD and CG-
GPSEEGY, the corresponding synuclein sequences with
three-residue extensions at the N-terminal end for coupling,
as immunogens. These peptides were coupled to sheep anti-
mouse IgG (Jackson ImmunoResearch Laboratories, West
Grove, PA) with sulfo-EMCS (Molecular Biosciences, Boul-
der CO). Sera were then purified with Protein A-Sepharose
and the antibodies were used at dilutions of 1:1000 (anti-α-
synD135) or 1:700 (anti-α-synY133). We also used the fol-
lowing commercially available primary antibodies: rabbit
polyclonal anti-ubiquitin (1:1000) from DAKO, rabbit mono-
clonal anti-PS129α-syn (1:2500 for electron microscopy,
otherwise 1:5000) from Abcam; mouse monoclonal anti-
PS129 α-syn (1:5000, WAKO); and rabbit polyclonal anti-full
length α-syn (1:1000) from Affinity Biologicals. For immuno-
histochemistry, we used the following secondary antibodies:goat anti-rabbit or anti-mouse IgG conjugated to Alexa
Fluor 488 (1:1000, Invitrogen), donkey anti-rabbit or anti-
mouse IgG conjugated to Cy3 (1:500, Jackson).
Mass spectrometry analysis (MS)
Sodium dodecyl sulfate (SDS)-soluble brain fractions
[16] were run on an SDS polyacrylamide (15%) gel,
which was then stained with Coomassie blue. Gel pieces
containing the proteins of interest were destained and
desiccated by incubation twice, for 20 min each, in 200
μl of 50 mM ammonium bicarbonate, 50% ethanol. Sam-
ples were then dried, incubated with modified trypsin
(12.5 ng/μl) overnight at 37°C and stored at −80°C. The
digested peptides were resuspended in 20 μl of 0.75% tri-
fluoroacetic acid (TFA), 60% acetonitrile, 300 mg/ml lac-
tic acid (solution A), loaded onto home-made titanium
tips [36], equilibrated with solution A and washed with
solution A supplemented with 0.1% TFA and 80% aceto-
nitrile (ACN). Samples were eluted twice with 0.5% am-
monium hydroxide and 0.5% piperidine. Eluted fractions
were acidified with formic acid (FA) and dried in a
Speedvac. Peptides were resuspended in 2% ACN/0.1%
FA for LC-MS/MS analysis (liquid chromatography -
MS). MS analysis was performed on an LTQ Orbitrap
XL (Thermo Fisher Scientific) equipped with a nanoAC-
QUITY system (Waters). Tandem MS was carried out in
an information-dependent mode, in which each full MS
analysis was followed by three MS/MS acquisitions, with
peptides selected for collision-induced dissociation (CID),
to generate tandem mass spectra. The results of the data
searches were imported into Scaffold (Version 3_00_8
Proteome Software) for the validation of protein identifi-
cation. Mascot 2.3 (Matrix Science) and SEQUEST in
Proteome Discoverer v.1.2 were used for data searches
against a database for the human and mouse α-syn forms,
and spectra were validated by manual inspection.
Production of recombinant proteins, in vitro
phosphorylation assays and western blot analyses
Early stop codons were introduced into the sequence
of wild-type α-syn, in the pT7.7 backbone, by single-site
mutagenesis with complementary oligonucleotides (α-
synD135, forward and reverse primers: gccttctgaggaa
gggtatcaagactaetaacctgaagcctaag, cttaggcttcaggttattagtc
ttgatacccttcctcagaaggc; α-synY133, forward and reverse
primers: ctgaggaagggtattaatgactacgaacctgaagcctaag, cttagg
cttcaggttcgtagtcattaatacccttcctcag). All constructs were ve-
rified by sequencing. The recombinant proteins were pro-
duced and phosphorylated by Polo-like kinase 3 (PLK3,
Invitrogen) as previously described [37,38]. Recombinant
proteins were resolved by SDS-PAGE in 4-12% polyacryl-
amide gels, electrotransferred to nitrocellulose membranes
and probed with anti-α-synD135 (1:400), anti-α-synY133
(1:400) or anti-α-syn (1:1000, Affiniti) antibodies. Antibody
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rabbit IgG (1:50000, Jackson Laboratories) and enhanced
chemiluminescence (West Pico Chemiluminescent sub-
strate, Pierce or West Dura Extended Duration Substrate,
Thermoscientific) with a Kodak Image J Station 4000 MM.
Statistical analyses
Unpaired two-tailed Student’s t-tests were used to compare
colocalization scores and the proportion of double-labeled
neuronal cell bodies or processes between mouse geno-
types hA30Pα-syn+/+ and parkin−/−; hA30Pα-syn+/+.
SAS software version 9.1 was used to analyze data from the
behavioral study. The extension reflex and the footprint
data were analyzed by repeated measures ANOVA, the
factors used for the linear models being age and genotype.
For the footprint analysis, the models included a linear, a
quadratic and a cubic term and were adjusted for weight.
Stepwise descending selection was used to eliminate non-
significant terms to obtain the most parsimonious model;
the difference from zero of each group was estimated with
nested models. Two genotypes were considered to be sig-
nificantly different if at least one of the linear, quadratic or
cubic factors of the model differed between them. All of
the differences observed concerned the cubic term. The p-
values reported for each graph therefore correspond to the
comparison of this term between groups. The final models
were as follows:
(1) Symmetry of the hind limb extension reflex: wild-
type = 0.03743.weight + 0.985 – 0.00239.age, hA30Pα-syn
+/+ = 0.03743.weight + 1.0863 – 0.02742.age – 0.001548.
age2 – 0.00003.age3, parkin+/−; hA30Pα-syn+/+ = 0.03743.
weight + 0.9866 – 0.02692.age – 0.000889.age2 – 0.00001.
age3, parkin−/−; hA30Pα-syn+/+ = 0.03743.weight +
1.0286 – 0.0143.age + 0.000664.age2 – 0.00000984.
age3, parkin−/−; hA30Pα-syn+/− = 0.03743.weight +
0.9833, parkin−/− = 0.03743.weight + 1.0504.
(2) Amplitude of the hind limb extension reflex: wild-
type = 0.1311.weight + 0.8324 – 0.2131.age + 0.005619.age2 –
0.00005.age3, hA30Pα-syn+/+ = 0.1311.weight – 0.00003.
age3, parkin+/−; hA30Pα-syn+/+ = 0.1311.weight – 0.00002.
age3, parkin−/−; hA30Pα-syn+/+ = 0.1311.weight + 1.2297 –
0.05299.age + 0.00021.age2, parkin−/−; hA30Pα-syn+/− =
0.1311.weight + 0.9174, parkin−/−= 0.1311.weight + 1.3363 –
0.00021.age2.
(3) Rotarod test: wild-type = 2.6585.weight + 110.04 –
1.41.age + 0.016.age2, hA30Pα-syn+/+ = 2.6585.weight +
138.88 – 5.42.age + 0.223.age2 – 0.00435.age3, parkin+/−;
hA30Pα-syn+/+ = 2.6585.weight + 98.17 – 0.00108.age3,
parkin−/−; hA30Pα-syn+/+ = 2.6585.weight + 112.46 –
0.00054.age3, parkin−/−; hA30Pα-syn+/− = 2.6585.weight +
107.98, parkin−/− = 2.6585.weight + 110.72.
(4) Length of forelimb stride: wild-type = 0.5815.weight +
5.1139 – 0.00000832.age3, hA30Pα-syn+/+ = 0.5815.weight
+ 4.6383 + 0.004034.age2 – 0.00015.age3, parkin+/−;hA30Pα-syn+/+ = 0.5815.weight + 5.3843 – 0.1668.age +
0.01054.age2 – 0.00019.age3, parkin−/−; hA30Pα-syn+/+ =
0.5815.weight + 5.5677 – 0.03991.age, parkin−/−; hA30Pα-
syn+/− = 0.5815.weight + 5.0679 parkin−/− = 0.5815.weight
+ 5.0634.
Results
Parkin depletion delays the appearance of motor dysfunction
in a dose-dependent manner in hA30Pα-syn mice
We previously reported that the loss of both alleles of
parkin significantly delayed the onset of hindlimb ex-
tension reflex asymmetry and the decline of rotarod
performance in hA30Pα-syn mice [16]. We evaluated
the effects of a single dysfunctional parkin allele on
disease-related changes in motor function in this
model, by analyzing in more detail the behavior of
hA30Pα-syn mice with no, one, or two dysfunctional
parkin alleles during a longitudinal follow-up study.
We assessed the performance of the animals in three
behavioral tasks: the hindlimb extension reflex, analyzed
here not only for loss of symmetry, but also for decline
in amplitude, (2) the rotarod test and (3) the footprint
test (Figure 1). The extension reflex data confirmed
the progressive impairment previously reported in
hA30Pα-syn mice (p < 0.0001 versus wild-type mice)
and its significantly later onset in mice with two
dysfunctional parkin alleles (p < 0.0001 for symmetry
and p < 0.01 for amplitude versus hA30Pα-syn+/+;
Figure 1A,B) [16]; a similar delay was observed for
hA30Pα-syn with a single dysfunctional parkin knock-
out allele (p < 0.0001 for symmetry and p < 0.01 for
amplitude versus hA30Pα-syn+/+). Similarly, the mean
rotarod performances of hA30Pα-syn mice declined
with age (p < 0.0001 versus wild-type mice; Figure 1C),
and this loss of performance was delayed in the ab-
sence of functional parkin alleles (p < 0.01 versus
hA30Pα-syn+/+); a significant, but less pronounced
delay, was also observed with a single parkin knockout
allele (p < 0.01 versus hA30Pα-syn+/+ and p < 0.0001
versus parkin−/−; hA30Pα-syn+/+). An analysis of gait
characteristics in the footprint test confirmed these ob-
servations (Figure 1D): the mean length of forepaw
strides decreased with age in hA30Pα-syn mice (p < 0.0001
versus wild-type mice); this decrease was delayed in mice
with no functional parkin alleles (p < 0.01 versus hA30Pα-
syn+/+) and, to a lesser extent, in hA30Pα-syn mice with a
single functional parkin allele (p < 0.05 versus parkin−/−;
hA30Pα-syn+/+).
Extension amplitude emerged as the earliest presymp-
tomatic impairment in each group, followed by a decline
in performance of the rotarod task, asymmetry in hind-
limb extension and a decrease in stride length (Table 1).
In each task, hA30Pα-syn mice with a single dysfunc-
tional parkin allele had an intermediate phenotype,
Figure 1 Parkin deficiency delays the appearance of motor dysfunction in hA30Pα-syn mice in a dose-dependent manner. Motor
functions were assessed with the extension reflex (A, B), the rotarod (C) and footprint (D) tests. For each test and for each genotype, the mean
performance scores are presented as a function of age (n = 11–14 per genotype); the curves correspond to the weight-adjusted models used for the
statistical comparisons. (E) The penetrance of the phenotype was calculated as the age at which the animals were unable to perform the rotarod test
(Kaplan-Meier analysis). *; **: different from hA30Pα-syn+/+ mice with p < 0.01; p < 0.0001; #; ##: different from parkin−/−; hA30Pα-syn+/+ mice, with
p < 0.05; p < 0.0001.
Fournier et al. BMC Neuroscience 2013, 14:135 Page 5 of 13
http://www.biomedcentral.com/1471-2202/14/135between that of hA30Pα-syn mice with no dysfunctional al-
lele and that of hA30Pα-syn mice with two dysfunctional
parkin alleles. The absence of Parkin lowered the penetrance
of the phenotype, defined as the proportion of animals un-
able to perform the rotarod task at a given age (Figure 1E),
whereas the partial depletion of Parkin had no such effect.Table 1 Age by which a 50% decrease in the mean test perform
case of the footprint test, within a confidence interval of one we
Amplitude of extension reflex
score < 2.5
Rotarod
< 90 s
hA30Pα-syn+/+ 18.1 ± 0.2 months 19.3 ± 0.2
parkin+/−; hA30Pα-syn+/+ 18.4 ± 0.2 months 20.2 ± 0.2
parkin−/−; hA30Pα-syn+/+ 21.0 ± 0.2 months 23.2 ± 0.2Truncated α-syn species found in LB accumulate in symptom-
atic hA30Pα-syn mice in the presence and absence of Parkin
We explored the mechanisms underlying the protection as-
sociated with Parkin deficiency, by comparing the accumu-
lation of pathological α-syn species in diseased hA30Pα-syn
mice with functional parkin, and in hA30Pα-syn mice withance of each group had occurred, or a 25% decrease in the
ek, determined from the mathematical models established
time on rod Symmetry of extension reflex
score < 1
Stride length
< 5 cm
months 20.0 ± 0.2 months 20.7 ± 0.2 months
months 22.3 ± 0.2 months 23.0 ± 0.2 months
months 23.4 ± 0.2 months > 24 months
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α-synY133 has been reported in the brains of PD patients
studied by biochemical techniques [2]. We investigated
the accumulation of these species in hA30Pα-syn mice,
using recently developed antibodies that we validated by
western blotting and immunohistochemistry. These anti-
bodies could not detect amounts below 1 μg of their cog-
nate recombinant protein, thus limiting their value for
biochemical studies (Figure 2A). However, the analysis of
more than 50 LB in substantia nigra sections from threeFigure 2 A new antibody reveals the presence of α-synD135 in the LB
antibodies directed against recombinant α-syn and its truncated versions. (B)
within LB, in a melanized dopaminergic neuron (brightfield image) in the sub
showing that the staining for α-synD135 in LB is abolished when the antibody
α-syn protein before immunohistochemistry. The blue signal corresponds to nucases of sporadic PD revealed immunostaining for α-
synD135 in more than 90% of these inclusions, detected
with PS129α-syn antibodies (Figure 2B). No such staining
was observed when the anti-α-synD135 antibody was pre-
absorbed with α-synD135, whereas prior incubation with
the full-length α-syn did not abolish the signal (Figure 2C).
By contrast, the preabsorption experiment revealed non-
specific staining with the antibody against α-synY133
(data not shown). This antibody was therefore not used in
subsequent experiments.of PD cases. (A) Immunoblot analysis with recently developed
Colocalization analysis of α-synD135 and PS129α-syn immunoreactivities
stantia nigra of a representative PD patient. (C) Control experiment
is absorbed with the truncated, but not with the full-length, recombinant
clear DNA stained with DAPI. Scale bar: 10 μm.
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species in hA30Pα-syn mice with functional or dysfunc-
tional parkin. In the brainstem of symptomatic animals,
the anti-α-synD135 antibody labeled numerous normally
shaped or swollen processes and cell bodies (Figure 3A).
This labeling was abolished by prior absorption with
recombinant α-synD135 (Figure 3A), and was not de-
tected in the brains of healthy hA30Pα-syn mice, re-
gardless of their expression status for parkin, or in non
transgenic animals (Figure 3B and data not shown).Figure 3 α-SynD135 accumulates specifically in the central nervous s
expression status. (A) Micrographs illustrating specific immunoreactivity i
hA30Pα-syn mouse with functional parkin alleles, stained with anti-α-synD1
α-synY133, full-length α-syn or α-synD135. Scale bars: 25 μm. (B) Comparat
atic and healthy hA30Pα-syn mice with functional parkin alleles; similar resu
Scale bars: 100 μm. (C) Representative spectrum illustrating the detection, b
1441 with z = 3) and α-synD135 (mass/charge = 1243 with z = 3) in the SDS
mice; peptides (sequence indicated in blue) were fragmented and unambiQualitative comparisons of symptomatic hA30Pα-syn
mice and hA30Pα-syn mice with no functional parkin
alleles revealed no obvious differences attributable to
Parkin deficiency in terms of the type of structures la-
beled (processes versus cell bodies) or the density of de-
posits (data not shown). MS analyses of brain lysates
from symptomatic mice unambiguously identified the
presence of α-syn and α-synD135 in both hA30Pα-syn
mice and hA30Pα-syn mice lacking Parkin (representa-
tive spectrum shown in Figure 3C). By contrast, theystem of symptomatic hA30Pα-syn mice, regardless of parkin
n coronal brainstem sections from a representative symptomatic
35 antibody before (left) and after absorption with recombinant
ive staining for α-synD135 in the brainstem of representative symptom-
lts were obtained in hA30Pα-syn mice with no functional parkin alleles.
y MS, of the C-terminal fragment of full-length α-syn (mass/charge =
-soluble fraction of proteins from brain lysates from hA30Pα-syn+/+
guously identified by tandem MS.
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weak in all cases, precluding clear identification of this
species (Table 2).
The α-synD135 species deposited are preferentially associ-
ated with PS129α-syn in the presence and absence of Parkin
In our previous study, we reported that ubiquitin immuno-
reactivity invariably colocalized with PS129α-syn staining in
symptomatic hA30Pα-syn mice. In addition, the PS129α-syn
deposits in neuronal cell bodies and processes were less fre-
quently associated with ubiquitin in mice with no func-
tional parkin alleles than in mice with functional parkin
[16]. Confocal analysis of a larger group of animals in this
study confirmed the colocalization of ubiquitin staining
and PS129α-syn deposits in symptomatic hA30Pα-syn mice,
regardless of their parkin status (Figure 4A, representative
Pearson’s correlation coefficient: 0.8 ± 0.07; Figure 5A). We
also confirmed that the proportion of PS129α-syn-positive
cell bodies associated with ubiquitin staining was lower in
mice with no functional parkin alleles than in mice with
functional parkin (Figure 5D, left graph). However, this dif-
ference was not significant for neuronal processes.
We investigated whether α-synD135 was phosphorylated
or ubiquitylated and whether there were differences in
these modifications associated with Parkin deficiency, by
performing double immunofluorescence staining on brain
sections from symptomatic hA30Pα-syn mice with func-
tional parkin or with no functional parkin alleles. Staining
for α-synD135 was significantly less abundant than staining
for PS129α-syn (Figure 5B) and ubiquitin (Figure 5C), in
mice of both genotypes. Consistent with the observations
in LB, most α-synD135 immunoreactivity was found to be
associated with PS129α-syn-positive deposits (Figure 5B and
Figure 5D, second graph from the left). However, it
often did not cover the entire PS129α-syn-positive struc-
ture within a particular neuronal cell body or process,
or extended beyond it (Figure 5B). The degree of co-
localization within regions displaying both types ofTable 2 Summary of the α-syn species detected by MS in
brain lysates from two hA30Pα-syn mice with functional
parkin (column # 1–2) and three hA30Pα-syn mice lacking
both parkin alleles (column # 3–5)
hA30Pα-syn+/+ parkin−/−; hA30Pα-syn+/+
# 1 # 2 # 3 # 4 # 5
Human α-syn + + + + + + + + + +
α-synD135 + + + + - + + +
α-synY133 - - - - -
Mouse α-syn + + + + + + + +
α-synD135 - - - - -
α-synY133 - - - - -
-: not detected; +: identified with a probability between 80% and 94%;
++: identified with a probability >95%.
Figure 4 Ubiquitin, and α-synD135 colocalize with PS129α-syn in
hA30Pα-syn mice, regardless of parkin expression status.
Analysis by confocal microscopy, showing the degree of
colocalization between (A) PS129α-syn and ubiquitin, (B) PS129α-syn
and α-synD135, and (C) ubiquitin and α-synD135, in coronal brain
sections from a representative symptomatic hA30Pα-syn mouse;
similar observations were made in hA30Pα-syn mice with two or no
functional parkin alleles (bregma −5.8). The projection stacks corres-
pond to sections of single immunostained cell bodies (upper panels)
and processes (lower panels) following the horizontal or vertical
dashed line in the Z-stack. Scale bars = 10 μm.immunoreactivity was high, regardless of parkin expres-
sion status (Figure 4B, representative Pearson’s corre-
lation coefficient: 0.9 ± 0.04). α-SynD135 and ubiquitin
Figure 5 Ubiquitin and α-synD135 associate preferentially with PS129α-syn deposits in hA30Pα-syn mice, regardless of parkin
expression status. Epifluorescence microscopy illustrating the association between (A) PS129α-syn and ubiquitin, (B) PS129α-syn and α-synD135, and (C)
ubiquitin and α-synD135, in hemi-brain sections from a representative symptomatic hA30Pα-syn mouse with normal parkin alleles (bregma −5.8). In blue:
nuclear DNA stained with DAPI. The left micrographs illustrate representative regions immunostained for each marker, at low magnification (Scale bars:
1000 μm), and the associated triad of micrographs are higher magnifications of areas within these regions (Scale bars: 20 μm). (D) Quantitative analysis of
the proportion of colabeled neuronal cell bodies and processes in hA30Pα-syn with two or no functional parkin alleles. (n= 6–10).
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http://www.biomedcentral.com/1471-2202/14/135colocalized in some neurons, but were also observed inde-
pendently of each other in approximately 50% of the neu-
ronal cell bodies and processes in symptomatic hA30Pα-
syn mice, regardless of parkin expression status (Figure 4C,representative Pearson’s correlation coefficients: 0.8 ± 0.03;
Figure 5C and D, graphs on the right).
We investigated the effect of truncation on α-syn phos-
phorylation at S129, by performing in vitro phosphorylation
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http://www.biomedcentral.com/1471-2202/14/135assays with PLK3, which is known to phosphorylate α-syn
efficiently and specifically at S129 [37,39]. After 15 h, the
entire pool of full-length α-syn was phosphorylated by
PLK3, whereas the α-synY133 variant was only partially
converted and phosphorylated α-synD135 was undetectable
after 15 h (Figure 6).
PS129α-syn accumulates as fibrillar species in symptomatic
hA30Pα-syn mice with and without Parkin
We used electron microscopy coupled to anti-PS129α-
syn-specific immunostaining to investigate the nature of
the deposits in regions of the brainstem in which a
massive accumulation of this protein was observed and
to explore potential differences associated with Parkin
deficiency. Abundant fibrils loosely associated and dif-
fusely distributed throughout the cytosol of neurons or
in neuronal processes were observed with secondary
antibodies conjugated to horseradish peroxidase, in
mice of both genotypes (representative images shown in
Figure 7A-C). There were no dense inclusions. The fi-
brils were generally more densely packed in the neur-
onal processes than in the cell bodies, and were, in
some cases, confined to the proximity of the plasma
membrane (Figure 7C). These fibrils were approxi-
mately 10–15 nm wide, as estimated for deposits immu-
nostained with secondary antibodies coupled to gold
beads (Figure 7D). Similar configurations were found inFigure 6 PLK3 does not phosphorylate α-synD135 efficiently in vitro.
α-syn, α-synD135 and α-synY133 by PLK3: the mass increase of approximathA30Pα-syn mice with functional parkin and with no
functional parkin alleles.
Discussion
This study confirms and extends our previous work
showing that the loss of both parkin alleles significantly
delays sensorimotor impairment related to the progres-
sion of α-synucleinopathy in hA30Pα-syn mice [16]. We
report here the results of a more complete comparative
behavioral longitudinal follow-up study of hA30Pα-syn
mice with two functional parkin alleles, or with the loss
of one or both parkin alleles. In addition to the rotarod
task and the analysis of hindlimb reflex symmetry, we
used the hindlimb reflex amplitude and footprint tests to
evaluate the behavior of the animals. Strikingly, this
follow-up not only confirmed our previous results, but
also revealed a protective effect of the loss of a single
parkin allele. In addition, Parkin depletion had a clear
dose-dependent effect on performance in the rotarod
task, with different performance curves for hA30Pα-syn
mice with two, one or no functional parkin alleles.
The loss of parkin expression delayed sensorimotor im-
pairment in hA30Pα-syn mice, but only slightly modified
neuropathological presentation in end-stage disease. The
extent and intensities of the immunoreactivities against
ubiquitin, PS129α-syn and α-syn truncated at D135 were
generally similar in hA30Pα-syn mice with and withoutMALDI-TOF time-point analyses of the phosphorylation of recombinant
ely 80 Da corresponds to the addition of one phosphate group.
A B C
A B D
Figure 7 PS129α-syn accumulates in fibrillar deposits in hA30Pα-syn mice. Representative electron micrographs illustrating a cell body (A)
and a process sectioned transversally (B) or longitudinally (C) and immunostained with PS129α-syn antibodies and secondary antibodies coupled
to horseradish peroxidase from a representative symptomatic hA30Pα-syn mouse expressing parkin. (A’-B’) are higher magnifications of the
framed regions in (A) and (B). (D) Nanogold staining of a PS129α-syn deposit within a neuronal process. Arrowheads indicate fibrils with (red) or
without (black) associated PS129α-syn staining; N (nucleus), M (mitochondria). Similar results were obtained in hA30Pα-syn mice with two or no
functional parkin alleles. Scale bars: 4 μm in (A) and (B), and 0.5 μm in (A’), (B’), (C) and (D).
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http://www.biomedcentral.com/1471-2202/14/135parkin expression. Consistent with the current hypothesis
that α-syn phosphorylated at S129 plays a key role in the
neuropathological process, PS129α-syn was deposited as
loose fibrils throughout the brainstem and the spinal cord
in affected animals only, regardless of parkin expression
status. In hA30Pα-syn mice of both parkin genotypes,
some of the PS129α-syn-positive deposits colocalized with
immunostaining for ubiquitin or α-synD135, which were
significantly less widely distributed than the PS129α-syn
staining, consistent with observations in human brains af-
fected by α-synucleinopathy. Ubiquitin and α-synD135
were mostly found concomitantly with PS129α-syn, indi-
cating that ubiquitylation and C-terminal truncation at
D135 are secondary PTM. As reported in our previous
study [16], the proportion of PS129α-syn deposits in
neuronal cell bodies associated with ubiquitin was
lower in hA30Pα-syn mice lacking both parkin alleles
than in hA30Pα-syn mice with functional parkin alleles,
possibly indicating less advanced α-synucleinopathy.
By contrast, parkin dysfunction was not associated with
any significant difference in the proportion of PS129α-
syn deposits costained for α-synD135, or in the degree
of colocalization between α-synD135- and ubiquitin-
immunoreactive protein deposits in the neuronal so-
mata or processes of hA30Pα-syn mice. It is widely
accepted that ubiquitylation is primarily associated with
PS129α-syn in human α-synucleinopathies, but less isknown about the crosstalk between S129 phosphorylation
and C-terminal truncation. Anderson et al. [2] reported
that all peptides corresponding to the α-synY133 fragment
identified by MS were phosphorylated at S129 in LB frac-
tions [2]. We found that recombinant α-synY133 and α-
synD135 proteins were less well phosphorylated by PLK3
than the full-length protein in vitro [37,39], suggesting that
C-terminal truncation does indeed occur once the protein
has been phosphorylated. However, the partial dissociation
between immunostaining for α-synD135 and that for
PS129α-syn often observed in the double-labeled neuronal
cell bodies and processes of hA30Pα-syn mice, regardless
of parkin expression, suggests that α-syn truncation at
D135 may also arise independently of phosphorylation on
S129. Alternatively, there may be interference between the
two types of immunohistochemical staining, due to the
physical proximity of the PTM examined: it is not unlikely,
for example, that a deposit of PS129α-syn with a high pro-
portion of truncated protein is less efficiently recognized by
antibodies specific for the phosphorylated species.
There is some debate about whether the ubiquitylation
of α-syn constitutes a proteasomal degradation signal [1],
but proteasome dysfunction, which is thought to occur
during the progression of α-synucleinopathy [29,40,41],
may generate C-terminally cleaved α-syn fragments
[12,42]. However, the random nature of the association
between the patterns of immunostaining for ubiquitin and
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tion playing a role in the generation of such fragments.
Despite the mitigation of the preclinical α-syn-related
phenotype revealed by our longitudinal behavioral follow-
up study, the partial depletion of Parkin did not delay overt
manifestation of the neurological phenotype in hA30Pα-
syn mice. The lack of impact of Parkin deficiency on dis-
ease penetrance and progression reported in hA53Tα-syn
mice [31], therefore does not exclude a moderate modifier
effect, as the study concerned was based on late-stage
neurological phenotypes and single-point analyses of spe-
cific behavioral measures. Alternatively, the absence of
interaction between Parkin and α-synA53T may reflect dif-
ferent effects of Parkin deficiency on the pathological alter-
ations caused by different α-syn variants [31]. However, a
recent in vitro study reported the rescue of cortical neurons
from the harmful effects of α-synA53T toxicity by siRNA-
mediated downregulation of the parkin gene, supporting
the notion that there is a beneficial modifier effect associ-
ated with this condition [43].
Conclusion
In conclusion, we confirm here that Parkin depletion modi-
fies α-syn-induced neurodegeneration in hA30Pα-syn mice.
The loss of a single functional parkin allele was sufficient
to delay the appearance of preclinical signs of motor dys-
function in this model, albeit to a lesser extent than ob-
served with the loss of both alleles, with no effect on
appearance of overt disease signs. An analysis of the α-syn
protein deposits revealed possible interplay between
PTM: ubiquitylation and truncation at D135 were associ-
ated preferentially with PS129α-syn, whereas ubiquitylation
and α-synD135 were found both independently and in as-
sociation. The distribution and composition of the PS129α-
syn deposits were similar in the presence and absence of
Parkin in the end stage of disease, suggesting that a loss of
Parkin function does not fundamentally alter the nature
of events leading to protein accumulation in this mouse
model. A detailed quantitative investigation of the pro-
teins, signaling and degradation pathways thought to
regulate α-syn-dependent neurodegeneration during
the preclinical and early symptomatic stages of the dis-
ease might shed light on the mechanisms underlying
the neuroprotection associated with Parkin deficiency
in future studies.
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